Compare TSHA & ATHM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TSHA | ATHM |
|---|---|---|
| Founded | 2019 | 2008 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.1B |
| IPO Year | 2020 | 2013 |
| Metric | TSHA | ATHM |
|---|---|---|
| Price | $5.45 | $16.85 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 1 |
| Target Price | $11.63 | ★ $28.00 |
| AVG Volume (30 Days) | ★ 2.2M | 445.9K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 9.83% |
| EPS Growth | ★ 5.56 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,773,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1,152.42 | $4.77 |
| P/E Ratio | ★ N/A | $12.13 |
| Revenue Growth | ★ 17.28 | N/A |
| 52 Week Low | $2.25 | $16.74 |
| 52 Week High | $7.30 | $29.92 |
| Indicator | TSHA | ATHM |
|---|---|---|
| Relative Strength Index (RSI) | 39.33 | 33.03 |
| Support Level | $5.37 | $16.74 |
| Resistance Level | $6.02 | $19.50 |
| Average True Range (ATR) | 0.43 | 0.59 |
| MACD | -0.18 | -0.20 |
| Stochastic Oscillator | 7.22 | 8.01 |
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.
Founded in 2008 as a media content platform, Autohome is the leading online automobile platform in China, ranking first among automotive service platforms in terms of mobile daily active users, according to QuestMobile. Through its two websites, autohome.com.cn and che168.com, Autohome delivers comprehensive, independent and interactive content and tools to automobile consumers as well as a full suite of services to automakers and dealers. According to iResearch, the company was the largest online automotive advertising and lead generation service provider, in terms of media services and lead generation revenue, in China's online auto platform media advertising market.